SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that treat cancer and benign diseases using heat therapy, today reported financial results for its third fiscal quarter ended May 31, 2013 including:
- Total revenue of $1.3 million for the third quarter ended May 31, 2013 increased by 100% when compared to total revenues in the third quarter of fiscal 2012
- Total revenue of $2.8 million for the nine months ended May 31, 2013 increased approximately 75% when compared to revenues in the same period a year ago
- Total hyperthermia backlog of approximately $2.3 million
- Cash and cash equivalents of $10.9 million; no debt
- Total stockholders’ equity of $14.1 million
“The growth in revenue during the third quarter and nine months ended May 31, 2013 when compared to the same periods in fiscal 2012 was chiefly derived from increased MicroThermX® Microwave Ablation sales,” said Harold Wolcott, President of BSD. “As planned, we commenced shipping MicroThermX systems and SynchroWave antennas to Terumo Europe NV during the third quarter.”
“The increases in our third quarter and year to date operating expenses are due mainly to our continuing roll out of the MicroThermX® product line and the support of our global distribution network. We also experienced significant nonrecurring expenses supporting our regulatory efforts around the world. Our balance sheet remains healthy with total cash of approximately $10.9 million and no long-term debt at the end of the third quarter,” concluded Wolcott.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market, and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Forward-Looking Statements
Statements contained in this press release that are not historical facts, including statements relating to our MicroThermX® line of products, are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission, including the market demand for our MicroThermX® products and the regulatory requirements we face. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.
| BSD MEDICAL CORPORATION | ||||||||||
| Condensed Balance Sheets | ||||||||||
| (Unaudited) | ||||||||||
|
ASSETS |
May 31, |
August 31, |
||||||||
| Current assets: | ||||||||||
| Cash and cash equivalents | $ | 10,882,122 | $ | 11,102,508 | ||||||
|
Accounts receivable, net of allowance for doubtful accounts of $20,000 |
1,199,843 |
289,587 |
||||||||
| Related party trade accounts receivable | 24,823 | 33,257 | ||||||||
| Inventories, net | 2,309,299 | 2,403,957 | ||||||||
| Other current assets | 201,609 | 120,069 | ||||||||
| Total current assets | 14,617,696 | 13,949,378 | ||||||||
| Property and equipment, net | 1,333,289 | 1,412,639 | ||||||||
| Patents, net | - | 4,032 | ||||||||
| $ | 15,950,985 | $ | 15,366,049 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||
| Current liabilities: | ||||||||||
| Accounts payable | $ | 385,334 | $ | 195,754 | ||||||
| Accrued liabilities | 423,419 | 424,698 | ||||||||
| Customer deposits | 876,230 | 24,980 | ||||||||
| Deferred revenue – current portion | 133,309 | 96,865 | ||||||||
| Total current liabilities | 1,818,292 | 742,297 | ||||||||
| Deferred revenue – net of current portion | 59,216 | 126,420 | ||||||||
| Total liabilities | 1,877,508 | 868,717 | ||||||||
| Commitments and contingencies | ||||||||||
| Stockholders’ equity: | ||||||||||
|
Preferred stock, $.001 par value; 10,000,000 shares authorized, no shares issued and outstanding |
- |
- |
||||||||
|
Common stock, $.001 par value, 80,000,000 shares authorized, 34,006,202 and 29,777,522 shares issued, respectively |
34,006 |
29,778 |
||||||||
| Additional paid-in capital | 57,466,759 | 51,845,035 | ||||||||
| Treasury stock, 24,331 shares at cost | (234 | ) | (234 | ) | ||||||
| Accumulated deficit | (43,427,054 | ) | (37,377,247 | ) | ||||||
| Total stockholders’ equity | 14,073,477 | 14,497,332 | ||||||||
| $ | 15,950,985 | $ | 15,366,049 | |||||||
|
BSD MEDICAL CORPORATION |
||||||||||||||||||
|
Condensed Statements of Comprehensive Loss |
||||||||||||||||||
|
(Unaudited) |
||||||||||||||||||
|
Three Months Ended |
Nine Months Ended |
|||||||||||||||||
| 2013 | 2012 | 2013 | 2012 | |||||||||||||||
| Revenues: | ||||||||||||||||||
| Sales | $ | 1,256,583 | $ | 611,730 | $ | 2,540,281 | $ | 1,165,655 | ||||||||||
| Sales to related parties | 230 | 13,757 | 76,776 | 315,163 | ||||||||||||||
| Equipment rental | 59,900 | 25,900 | 178,700 | 101,450 | ||||||||||||||
| Total revenues | 1,316,713 | 651,387 | 2,795,757 | 1,582,268 | ||||||||||||||
| Cost of Revenues: | ||||||||||||||||||
| Cost of sales | 713,383 | 435,656 | 1,533,618 | 934,070 | ||||||||||||||
| Cost of related party sales | 81 | 12,180 | 66,527 | 226,363 | ||||||||||||||
| Cost of equipment rental | 2,947 | 2,947 | 8,841 | 8,841 | ||||||||||||||
| Total cost of revenues | 716,411 | 450,783 | 1,608,986 | 1,169,274 | ||||||||||||||
| Gross margin | 600,302 | 200,604 | 1,186,771 | 412,994 | ||||||||||||||
| Operating costs and expenses: | ||||||||||||||||||
| Research and development | 607,690 | 641,457 | 1,693,648 | 1,760,803 | ||||||||||||||
| Selling, general and administrative | 1,967,082 | 1,667,503 | 5,562,013 | 4,580,000 | ||||||||||||||
| Total operating costs and expenses | 2,574,772 | 2,308,960 | 7,255,661 | 6,340,803 | ||||||||||||||
| Loss from operations | (1,974,470 | ) | (2,108,356 | ) | (6,068,890 | ) | (5,927,809 | ) | ||||||||||
| Other income (expense): | ||||||||||||||||||
| Interest income | 7,708 | 13,861 | 24,374 | 47,890 | ||||||||||||||
| Other expense | (2,984 | ) | (2,371 | ) | (5,291 | ) | (6,950 | ) | ||||||||||
| Total other income | 4,724 | 11,490 | 19,083 | 40,940 | ||||||||||||||
| Loss before income taxes | (1,969,746 | ) | (2,096,866 | ) | (6,049,807 | ) | (5,886,869 | ) | ||||||||||
| Provision for income taxes | - | (988 | ) | - | (988 | ) | ||||||||||||
| Net loss and comprehensive loss | $ | (1,969,746 | ) | $ | (2,097,854 | ) | $ | (6,049,807 | ) | $ | (5,887,857 | ) | ||||||
| Net loss per common share: | ||||||||||||||||||
| Basic | $ | (0.06 | ) | $ | (0.07 | ) | $ | (0.20 | ) | $ | (0.20 | ) | ||||||
| Diluted | $ | (0.06 | ) | $ | (0.07 | ) | $ | (0.20 | ) | $ | (0.20 | ) | ||||||
|
Weighted average number of shares outstanding: |
||||||||||||||||||
| Basic | 32,042,000 | 29,717,000 | 30,541,000 | 29,696,000 | ||||||||||||||
| Diluted | 32,042,000 | 29,717,000 | 30,541,000 | 29,696,000 | ||||||||||||||
